A 47-year-old man with a 2-year history of Philadelphia chromosome-positive chronic phase (CP) chronic myeloid leukaemia (CML) underwent autologous PBSCT. During the period of haemopoietic reconstitution he underwent five leucapheretic (LP) harvests yielding a total of 2.6 ؋ 10 6 /kg CD34 + cells. Cytogenetic analyses revealed 94, 83, 83, 96 and 85% Ph negativity respectively for the five harvests. RT-PCR analyses for BCR-ABL performed on randomly picked CFU-GM from the five LP products were negative in all cases. These observations suggest that the majority of harvested cells, including the more primitive clonogenic cells, were BCR-ABL (Ph) negative and presumably were not part of the leukaemic clone. These findings support the notion that autologous PBSCT in CML whilst serving as a therapeutic manoeuvre may also facilitate the collection of non-leukaemic progenitor cells for further transplantation procedures. Keywords: CML; PBSCT; leucapheresis; purging Potentially curative alloSCT is presently unavailable to the majority of CML patients because of patient age and/or the lack of availability of a suitably matched donor.
Potentially curative alloSCT is presently unavailable to the majority of CML patients because of patient age and/or the lack of availability of a suitably matched donor. 1 Interferon is reported in some multicentre randomised studies to be associated with a prolongation of survival when compared to chemotherapy, 2, 3 however, no discernible plateauing of survival curves has been demonstrated, thus suggesting that IFN is unlikely to be curative. Comparison with historical controls suggests that autologous PBSCT may be associated with a prolongation of survival for CP CML patients and in instances can result in prolonged periods of Philadelphia chromosome-negative haemopoiesis. 4 Thus, the demonstration that significant numbers of Ph-negative peripheral blood MNC could be obtained by LP after the administration of high-dose chemotherapy 5 has led to the development of numerous therapeutic strategies based on this perceived in vivo purging effect. Whether PBSCT following in vivo purging is more beneficial when compared to the use of unmanipulated PBSC is uncertain but theoretically it is a more attractive approach. Based on these observations we chose to examine whether sufficient numbers of PBSC could be obtained during the recovery phase from PBSCT to enable a second autografting procedure, thus combining a potential therapeutic benefit with high-dose chemotherapy in vivo purging and subsequent progenitor cell collection.
Case report
In March 1995, a 47-year-old male was incidentally found to have a total leucocyte count of 97 ϫ 10 9 /l with a normal haemoglobin and platelet count. The peripheral blood features were consistent with CP CML. Bone marrow aspirate confirmed the diagnosis with 100% of metaphases showing t(9;22)(q34;q11). RT-PCR revealed b2a2 BCR-ABL transcripts. Initial disease control was achieved with hydroxyurea. He was then started on daily alpha-interferon (IFN) and received subcutaneous cytosine-arabinoside on a monthly basis for a total of 12 months. Repeat bone marrow cytogenetic analysis on recovery from the final course of cytosine-arabinoside revealed 82% Ph-chromosome negativity. He was then maintained on IFN at his previous dose of 9 ϫ 10 6 units daily. A bone marrow aspirate 4 months later showed cytogenetic deterioration with only 58% Ph chromosome negativity. After discussion with the patient, the IFN was ceased and a PBSC harvest arranged. In January 1997 he received 5 g/m 2 of cyclophosphamide and on the fifth day following this he was started on G-CSF 5 g/m 2 subcutaneously daily. LP was undertaken on two occasions (days +9 and +10) when the WBC had risen to Ͼ1.0 ϫ 10 9 /l. Cytogenetic analysis on the two LP products revealed 15 and 50% Ph negativity respectively. A total of 23.6 ϫ 10 6
CD34
+ cells/kg were collected and cryopreserved. Approximately 2 months later the patient was readmitted for PBSCT and an elective second PBSC harvest procedure. He received high-dose busulphan (4 mg/kg/day in four divided doses for 4 days) and 48 h following completion was reinfused with 12 ϫ 10 6 CD34 + cells/kg (50% Ph-negative). On day +5 post-reinfusion he was started on G-CSF 5 g/m 2 subcutaneously. By day +12 his total leucocyte count had risen to 1.1 ϫ 10 9 /l and he started daily LP harvests ( Figure 1 ). These were completed with no significant complications. At his most recent follow-up he was well with total leucocytes of 3.3 ϫ 10 9 /l, platelets 104 ϫ 10 9 /l and haemoglobin 141 g/l on no specific therapy. Bone marrow aspirate revealed adequate engraftment and 95% Ph chromosome negativity on FISH studies.
Materials and methods

CFU-GM assays and CD34
+ cell numbers
Triplicates of 0.4 ϫ 10 5 PBMC from each of the post-PBSCT LP products were established in 1 ml of Methocult-GF (Stemcell Technologies, Vancouver, Canada) and incubated at 37°C with 5% CO 2 . Day 14 colonies (Ͼ50 cells) were counted and six to eight colonies of 50-500 cells each were randomly picked from each harvest (36 in total). These were immediately placed in 500 l guanidium thiocyanate solution, sheared through a 23 G needle and vortexed for 30 s prior to storing at −20°C. The CD34 + content of the LP products were determined by flow cytometry (EPICS Profile II; Coulter Electronics, Sydney, Australia) after staining of cells with FITC-conjugated anti-CD34 antibody (Becton-Dickinson, Sydney, Australia).
Reverse transcription and RT-PCR
Total RNA was prepared from the colony lysates by the method of Chomczynski and Sacchi 6 after the addition of 40 g of carrier tRNA and cDNA was synthesized as previously described. 7 The presence of amplifiable cDNA was assessed by single-step RT-PCR for ABL and two-step RT-PCR for BCR-ABL was then performed on the colonies positive for ABL. 8 In each case 5 l of PCR product were electrophoresed through ethidium bromide-stained 2% agarose gels and visualised under UV light. Positive control cDNA derived from the cell line KCL22 and GTC lysate, cDNA synthesis and PCR blanks were also analysed. 
Cytogenetic analyses and in situ hybridisation
Cytogenetic studies were performed on FUDR + uridinesynchronised 48-h unstimulated bone marrow and LP product cultures. Cytogenetic slides were prepared by standard methods and GTG banding was used for karyotype analysis. When insufficient metaphases were produced for analysis (LP1, 2 and 4) FISH was performed on air-dried cytospin preparations of the initial cell suspensions using a commercially available probe (Vysis, Illinois, USA) for the BCR-ABL translocation. A minimum of 200 cells was scored for the fusion product according to the manufacturer's protocol.
Results
Haemopoietic recovery following PBSCT was brisk and uncomplicated ( Figure 1 ) requiring minimal platelet support and no red blood cell support. Neutrophil engraftment (Ͼ0.5 ϫ 10 9 /l) occurred on day +12 and platelet engraftment (20 ϫ 10 9 /l) on day +17. LP was commenced at a total leucocyte count of 1.1 ϫ 10 9 /l and continued for 5 successive days. MNC, CFU-GM and CD34
+ cell numbers obtained from each LP product are outlined in Table 1 . A total of 2.6 ϫ 10 6 CD34 + cells/kg and 29.1 ϫ 10 4 CFU-GM/kg were obtained and would be considered adequate for haemopoietic reconstitution following myeloablation.
Standard cytogenetic analyses of the LP product were performed on LP3 (29 metaphases) and LP5 (33 metaphases) revealing 83 and 85% Philadelphia negativity, respectively. FISH was undertaken on material from the remaining collections due to the small numbers of analysable metaphases obtained, revealing 94, 83 and 96% Philadelphia negativity on LP1, LP2 and LP4, respectively. A total of 36 CFU-GM were randomly picked and cDNA successfully produced (as shown by successful single-step PCR for ABL) from 31 of these; LP1, five colonies; LP2, seven colonies; LP3, six colonies; LP4, seven colonies and LP5, six colonies. Nested PCR for BCR-ABL was negative on duplicate analyses in all instances.
Discussion
That haemopoietic reconstitution following PBSCT for CML with unmanipulated cells may be Ph-negative is well recognised and is consistent with the notion that, at least initially, normal haemopoiesis may have a proliferative advantage compared with Ph positive haemopoiesis. 9 It is this observation that provided the rationale for our attempt at Ph-negative progenitor cell collection during the post-PBSCT phase. In this instance, we were able to obtain sufficient CD34
+ cells to enable a further PBSCT procedure to be undertaken if clinically warranted. Furthermore, this was achieved without any discernible prolongation of expected engraftment times and the maintenance on followup of adequate haemopoiesis. The ability to collect sufficient progenitor cells post-PBSCT may be technically easier in patients who have received less intensive preceding standard therapy and are at an earlier stage of their disease and this possibility warrants further investigation. Cytogenetic and FISH analysis showed a low level of Ph positivity from all five LP collections. However, the lineage of these cells and their level of differentiation is uncertain. In view of this the demonstration of exclusively BCR-ABLnegative CFU-GM is not an inconsistent observation. The cytogenetic detection of Ph positivity may represent surviving mononuclear cells which are more terminally differentiated than CFU-GM, with the more primitive cells, possibly including those capable of long-term haemopoietic engraftment, being non-leukaemic in origin. The possibility that the CFU-GM were leukaemic in origin but did not express BCR-ABL is unlikely based on previously described analyses of CP CML CFU-GM. 10 The use of RT-PCR and more complex cellular assays such as the Delta assay described by Gordon 11 would enable more informed conclusions to be made concerning the origin of cells ancestral to CFU-GM.
A possible survival advantage has been demonstrated for patients undergoing sequential unmanipulated autologous PBSCT during transformed CML compared to patients who undergo a single PBSCT. 12 It is not unreasonable to assume that a similar advantage may be seen in patients with less advanced disease who undergo sequential rather than single autograft procedures. Thus, the ability to successfully collect non-leukaemic progenitor cells following autografting for CP CML, if confirmed by others, would facilitate the use of sequential PBSCT procedures in CML with the initial PBSCT acting as an in vivo purging step.
